

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

NCT05130437

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	ModernaTX, Inc.
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (2)

- Participated in Study mRNA-3927-P101.
- Completed the EOT/ET visit in Study mRNA-3927-P101 and enroll in this study such that the first dose in this study is planned to be within 14±3 days of the last dose of mRNA-3927 in the mRNA-3927-P101 study.

Exclusion (3)

- Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
- Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
- History of liver and/or kidney transplant.

Locations (22 total)

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
University of Stanford Medical Center, Palo Alto, California, United States
University of Michigan Hospitals, Ann Arbor, Michigan, United States
... and 19 more locations